Replies to post #820 on Iovance Biotherapeutics Inc (IOVA)

[Sunman88]

Hopefully they achieve 250 patients in 2024 and point to 500 in 2025 and 800 in 2026 to break even: They will need to refinance by 2025 Q2.. This is an overhang. Hopefully, they dilute 20M shares above $15 after they announce positive Phase 3 results or positive Phase 2 for NSCLC. After that there is no looking back. A buyout at that time would sweeten everything.